Dr. Xinmin Yu 余新民
Chief Physician
Department of Medical Oncology for Thoracic Tumors, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and immunotherapy for lung cancer, esophageal cancer, malignant pleural mesothelioma, and thymoma. Focuses on molecular targeted therapy and managing drug resistance in thoracic malignancies.
Chief Physician and Deputy Director of the Thoracic Oncology Department ward at Zhejiang Cancer Hospital. Participated in more than 30 domestic and international multicenter clinical studies and has extensive experience in applying new-generation anti-tumor drugs.
Professional roles
- Vice Chair, Lung Cancer Professional Committee, Zhejiang Cancer Prevention and Control Alliance
- Member, Chemotherapy Professional Committee, Zhejiang Anti-Cancer Association
- Member, Clinical Immunology Professional Committee, Zhejiang Province
- Member, International Association for the Study of Lung Cancer
Name order: in Chinese the family name comes first (Yu Xinmin). Papers usually list the name as Xinmin Yu or Yu X.
Selected publications
83 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Clin Oncol, 2024 (senior author): Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second‑line monotherapy for metastatic esophageal squamous cell carcinoma: A prospective study. PubMed 38414510
- Transl Lung Cancer Res, 2020 (senior author): cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma. PubMed 32676342
- Oncogene, 2020 (senior author): Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. PubMed 31831835
- Oncogene, 2020 (senior author): Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. PubMed 31754213
- Lung Cancer, 2019 (senior author): Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. PubMed 31027700
- Lung Cancer, 2018 (senior author): Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. PubMed 30268447
- Oncotarget, 2016 (senior author): Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. PubMed 27528220
- Sci Rep, 2016 (senior author): Comparison of the 7(th) and proposed 8(th) editions of the AJCC/UICC TNM staging system for non-small cell lung cancer undergoing radical surgery. PubMed 27641932
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion